Syros stock rises as tamibarotene gets FDA fast track status for rare blood cancer

FDA written on wooden cube with keyboard , calculator, chart,glasses.Business concept

Iryna Drozd

The U.S. Food and Drug Administration (FDA) granted fast track designation to Syros Pharmaceuticals’ (NASDAQ:SYRS) tamibarotene to treat higher-risk myelodysplastic syndrome (HR-MDS).

MDS are a group of cancers in which immature blood cells in the bone marrow

Source link

5 Trading strategies to make money

Looking to boost your trading profits?

Get you copy of our FREE Ebook Now !!!